Pantop%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520d

# Pantoprazole ## Overview Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion. ## Primary Indications * Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD). * Maintenance of healing of erosive esophagitis. * Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome). ## Adult Dosing * **Healing of Erosive Esophagitis:** 40 mg orally or intravenously once daily for up to 8 weeks. * **Maintenance of Healing:** 40 mg orally once daily. Some patients may be treated with 20 mg orally once daily. * **Pathological Hypersecretory Conditions:** Starting dose is 40 mg orally or intravenously twice daily. Doses may be adjusted based on clinical response. Doses up to 240 mg daily have been administered intravenously. ## Pediatric Dosing * **GERD (Erosive Esophagitis):** * **12 to 16 years:** 40 mg orally once daily for up to 8 weeks. * **5 to 11 years:** 20 mg orally once daily for up to 8 weeks. * **2 to less than 5 years:** 25 mg orally once daily for up to 8 weeks. * Dosing for younger children or for other indications in pediatrics may be extrapolated from adult data or based on specific protocols. ## Dose Adjustments No dose adjustment is generally needed for hepatic impairment for the oral formulation, but caution is advised. For IV formulations, caution is advised in moderate to severe hepatic impairment. No dose adjustment is required for renal impairment. ## Contraindications Known hypersensitivity to pantoprazole or any component of the formulation, or to other substituted benzimidazoles. ## Adverse Effects Common adverse effects include headache, diarrhea, nausea, abdominal pain, vomiting, dizziness, and flatulence. Long-term use may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), hypomagnesemia, and vitamin B12 deficiency. ## Key Drug Interactions * **Drugs requiring gastric acid for absorption:** Pantoprazole can decrease absorption of drugs like ketoconazole, itraconazole, and certain antiretrovirals (e.g., atazanavir, nelfinavir). * **Methotrexate:** PPIs may increase methotrexate levels, potentially leading to toxicity. * **CYP2C19 Substrates:** Pantoprazole is a moderate inhibitor of CYP2C19. Caution and potential dose adjustment may be needed for drugs like clopidogrel, though clinical significance is debated. ## Monitoring * Monitor for signs and symptoms of *Clostridium difficile* infection. * Consider monitoring serum magnesium levels, especially with prolonged use (>1 year) or concurrent diuretic use. * Assess for signs of bone fracture risk with long-term therapy. * Monitor for signs of vitamin B12 deficiency with prolonged use. ## Clinical Pearls * For oral administration, swallow capsules or tablets whole. Do not crush or chew. * Delayed-release formulations should be taken at least 30 minutes before a meal. * Intravenous administration should be given over at least 15 minutes. * The maximum recommended daily dose for pathological hypersecretory conditions can be higher than for other indications, but should be guided by clinical response and local protocols. **Disclaimer:** This information is for educational purposes only and does not substitute for professional medical advice. Always consult with a qualified healthcare provider to ensure the information provided is accurate and appropriate for your specific situation. Verify current prescribing information with the official product labeling.